Use este identificador para citar ou linkar para este item: https://repositorio.ufpa.br/jspui/handle/2011/5695
Registro completo de metadados
Campo DCValorIdioma
dc.creatorBARBEDO, Mayara de Brito-
dc.creatorRICCI, Ricardo-
dc.creatorJIMENEZ, Maria Carolina Sarti-
dc.creatorCUNHA, Maristela Gomes da-
dc.creatorYAZDANI, Syed S-
dc.creatorCHITNIS, Chetan E-
dc.creatorRODRIGUES, Mauricio Martins-
dc.creatorSOARES, Irene da Silva-
dc.date.accessioned2014-09-11T17:21:22Z-
dc.date.available2014-09-11T17:21:22Z-
dc.date.issued2007-06-
dc.identifier.citationBARBEDO, Mayara B et al. Comparative recognition by human IgG antibodies of recombinant proteins representing three asexual erythrocytic stage vaccine candidates of Plasmodium vivax. Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, v. 102, n. 3, p. 335-340, jun. 2007. Disponível em: <http://www.scielo.br/pdf/mioc/v102n3/5787.pdf>. Acesso em: 16 jun. 2014. <http://dx.doi.org/10.1590/S0074-02762007005000040>.pt_BR
dc.identifier.issn0074-0276-
dc.identifier.urihttp://repositorio.ufpa.br/jspui/handle/2011/5695-
dc.description.abstractIn previous immuno-epidemiological studies of the naturally acquired antibody responses to merozoite surface protein-1 (MSP-1) of Plasmodium vivax, we had evidence that the responses to distinct erythrocytic stage antigens could be differentially regulated. The present study was designed to compare the antibody response to three asexual erythrocytic stage antigens vaccine candidates of P. vivax. Recombinant proteins representing the 19 kDa C-terminal region of MSP-1(PvMSP19), apical membrane antigen n-1 ectodomain (PvAMA-1), and the region II of duffy binding protein (PvDBP-RII) were compared in their ability to bind to IgG antibodies of serum samples collected from 220 individuals from the state of Pará, in the North of Brazil. During patent infection with P. vivax, the frequency of individuals with IgG antibodies to PvMSP119, PvAMA-1, and PvDBP-RII were 95, 72.7, and 44.5% respectively. Although the frequency of responders to PvDBP-RII was lower, this frequency increased in individuals following multiple malarial infections. Individually, the specific antibody levels did not decline significantly nine months after treatment, except to PvMSP119. Our results further confirm a complex regulation of the immune response to distinct blood stage antigens. The reason for that is presently unknown but it may contribute to the high risk of re-infection in individuals living in the endemic areas.pt_BR
dc.description.provenanceSubmitted by Edisangela Bastos (edisangela@ufpa.br) on 2014-08-28T20:40:16Z No. of bitstreams: 2 license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) Artigo_ComparativeRecognitionHuman.pdf: 75630 bytes, checksum: d9874905f74e14b1a8bb1e8b43f8df56 (MD5)en
dc.description.provenanceApproved for entry into archive by Albirene Aires (albireneufpa@gmail.com) on 2014-09-11T17:21:22Z (GMT) No. of bitstreams: 2 license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) Artigo_ComparativeRecognitionHuman.pdf: 75630 bytes, checksum: d9874905f74e14b1a8bb1e8b43f8df56 (MD5)en
dc.description.provenanceMade available in DSpace on 2014-09-11T17:21:22Z (GMT). No. of bitstreams: 2 license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) Artigo_ComparativeRecognitionHuman.pdf: 75630 bytes, checksum: d9874905f74e14b1a8bb1e8b43f8df56 (MD5) Previous issue date: 2007-06en
dc.language.isoengpt_BR
dc.rightsAcesso Aberto-
dc.subjectMaláriapt_BR
dc.subjectPlasmodium vivaxpt_BR
dc.subjectAnticorpospt_BR
dc.subjectImunologiapt_BR
dc.subjectImunoglobina G (IgG)pt_BR
dc.subjectProteínaspt_BR
dc.subjectAntígenopt_BR
dc.subjectAnticorpos tipo IgGpt_BR
dc.titleComparative recognition by human IgG antibodies of recombinant proteins representing three asexual erythrocytic stage vaccine candidates of Plasmodium vivaxpt_BR
dc.typeArtigo de Periódicopt_BR
Aparece nas coleções:Artigos Científicos - ICB

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
Artigo_ComparativeRecognitionHuman.pdf73,86 kBAdobe PDFVisualizar/Abrir


Este item está licenciado sob uma Licença Creative Commons Creative Commons